Tata Memorial Centre asserts that its Rs 100 per tablet medication has the potential to prevent cancer recurrence. The tablet, developed by the institute, aims to not only prevent cancer from returning but also reduce treatment side effects by half. Currently awaiting approval from FSSAI, once sanctioned, the tablet is anticipated to be available in the market by June.
Trending
- Centre Unveils ₹17-Trillion PPP Infra Pipeline with 852 Projects, Highways Dominate
- Reliance Industries Shares Tumble 4.5% as Retail Competition Concerns Spook Investors
- Gold, Silver Extend Four-Day Rally, Edge Closer to Record Highs on Safe-Haven Demand
- Sebi Proposes 30-Day Lag on Use of Market Data for Educational Purposes
- ITC Stock Slides to 52-Week Low as New Cigarette Tax Spooks Investors
- Gabion Technologies IPO Subscribed 57x on Day 1
- Indian Crude Oil Basket Falls Below $60 a Barrel for First Time Since 2021
- Turtlemint to File Updated Draft Papers Soon, Eyes ₹2,000-Crore IPO by April
- FPIs Turn Net Sellers, DIIs Support Markets as Sensex, Nifty End Lower
- Silver Hallmarking May Turn Mandatory as Centre Reviews BIS Framework
Ensuring Authenticity, Upholding Trust
